

# Luiz Eduardo Wildemberg

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3684901/luiz-eduardo-wildemberg-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

14  
papers

249  
citations

8  
h-index

14  
g-index

14  
ext. papers

327  
ext. citations

4.3  
avg, IF

3.49  
L-index

#	Paper	IF	Citations
14	Prolactinomas. <i>Presse Medicale</i> , <b>2021</b> , 50, 104080	2.2	1
13	The future of somatostatin receptor ligands in acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> ,	5.6	5
12	Machine Learning-based Prediction Model for Treatment of Acromegaly With First-generation Somatostatin Receptor Ligands. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> , 106, 2047-2056	5.6	7
11	Mutation Is Not a Molecular Biomarker of Long-Term Response to First-Generation Somatostatin Receptor Ligands in Acromegaly. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3
10	Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles. <i>Scientific Reports</i> , <b>2019</b> , 9, 1122	4.9	13
9	Treatment escape reduces the effectiveness of cabergoline during long-term treatment of acromegaly in monotherapy or in association with first-generation somatostatin receptor ligands. <i>Clinical Endocrinology</i> , <b>2018</b> , 88, 889-895	3.4	14
8	Precision medicine in the medical management of pituitary tumors. <i>Current Opinion in Endocrine and Metabolic Research</i> , <b>2018</b> , 1, 57-62	1.7	2
7	Predictors of surgical outcome and early criteria of remission in acromegaly. <i>Endocrine</i> , <b>2018</b> , 60, 415-424		36
6	Molecular evidence and clinical importance of $\beta$ arrestins expression in patients with acromegaly. <i>Journal of Cellular and Molecular Medicine</i> , <b>2018</b> , 22, 2110-2116	5.6	12
5	Apoplexy in nonfunctioning pituitary adenomas. <i>Pituitary</i> , <b>2018</b> , 21, 138-144	4.3	31
4	MANAGEMENT OF ENDOCRINE DISEASE: Personalized medicine in the treatment of acromegaly. <i>European Journal of Endocrinology</i> , <b>2018</b> , 178, R89-R100	6.5	41
3	Somatostatin receptor ligands in the treatment of acromegaly. <i>Pituitary</i> , <b>2017</b> , 20, 100-108	4.3	62
2	Somatotropinomas inadequately controlled with octreotide may over-respond to pasireotide: the importance of dose adjustment to achieve long-term biochemical control. <i>Hormones</i> , <b>2017</b> , 16, 84-91	3.1	6
1	Pasireotide for the treatment of acromegaly. <i>Expert Opinion on Pharmacotherapy</i> , <b>2016</b> , 17, 579-88	4	16